Blood pressure-dependent and independent effects of agents that inhibit the renin–angiotensin system
暂无分享,去创建一个
M. Pfeffer | M. Woodward | A. Zanchetti | S. MacMahon | F. Turnbull | J. Chalmers | B. Neal | J. Kostis | C. Algert | B. Neal
[1] G. Mancia,et al. Angiotensin II receptor blockers and myocardial infarction: deeds and misdeeds , 2005, Journal of hypertension.
[2] R. Tsuyuki,et al. Angiotensin receptor blockers and risk of myocardial infarction: systematic review , 2005, BMJ : British Medical Journal.
[3] B. Williams. Recent hypertension trials: implications and controversies. , 2005, Journal of the American College of Cardiology.
[4] R. Schmieder,et al. Aliskiren, a Novel Orally Effective Renin Inhibitor, Provides Dose-Dependent Antihypertensive Efficacy and Placebo-Like Tolerability in Hypertensive Patients , 2005, Circulation.
[5] S. Verma,et al. Angiotensin receptor blockers and myocardial infarction , 2004, BMJ : British Medical Journal.
[6] M. Pfeffer,et al. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. , 2004, The New England journal of medicine.
[7] J. Laragh,et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial , 2004, The Lancet.
[8] S. Hosoda,et al. Comparison of nifedipine retard with angiotensin converting enzyme inhibitors in Japanese hypertensive patients with coronary artery disease: the Japan Multicenter Investigation for Cardiovascular Diseases-B (JMIC-B) randomized trial. , 2004, Hypertension research : official journal of the Japanese Society of Hypertension.
[9] J. Ménard,et al. Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin: randomised, double blind, placebo controlled trial (the DIABHYCAR study) , 2004, BMJ : British Medical Journal.
[10] Karl Swedberg,et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. , 2003, The New England journal of medicine.
[11] M. Pfeffer,et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme , 2003, The Lancet.
[12] Karl Swedberg,et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial , 2003, The Lancet.
[13] Karl Swedberg,et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial , 2003, The Lancet.
[14] J. Gayet. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. , 2003, Journal of hypertension.
[15] A. Hofman,et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial , 2003, Journal of hypertension.
[16] C. Reid,et al. A comparison of outcomes with angiotensin-converting--enzyme inhibitors and diuretics for hypertension in the elderly. , 2003, The New England journal of medicine.
[17] J. Staessen,et al. If only cardiologists did properly measure blood pressure. Blood pressure recordings in daily practice and clinical trials. , 2002, Journal of the American College of Cardiology.
[18] B. Davis,et al. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). , 2002, JAMA.
[19] Tom Greene,et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. , 2002, JAMA.
[20] J. Rouleau,et al. Ischemia Management with Accupril post bypass Graft via Inhibition of angiotensin coNverting enzyme (IMAGINE): a multicentre randomized trial - design and rationale. , 2002, The Canadian journal of cardiology.
[21] K. Dickstein,et al. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial , 2002, The Lancet.
[22] M. Nieminen,et al. For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .
[23] P. Mehler,et al. Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. , 2002, Kidney international.
[24] M. Woodward,et al. Randomised trial of a perindopril-based blood pressure lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack , 2001 .
[25] E. Lewis,et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. , 2001, The New England journal of medicine.
[26] Keith C. Norris,et al. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. , 2001, JAMA.
[27] R. Lees,et al. The QUinapril Ischemic Event Trial (QUIET): evaluation of chronic ACE inhibitor therapy in patients with ischemic heart disease and preserved left ventricular function. , 2001, The American journal of cardiology.
[28] B Neal,et al. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials , 2000, The Lancet.
[29] K. Teo,et al. Long-Term Effects of Cholesterol Lowering and Angiotensin-Converting Enzyme Inhibition on Coronary Atherosclerosis: The Simvastatin/Enalapril Coronary Atherosclerosis Trial (SCAT) , 2000, Circulation.
[30] John S. Scott,et al. Randomized, placebo-controlled trial of the angiotensin-converting enzyme inhibitor, ramipril, in patients with coronary or other occlusive arterial disease. PART-2 Collaborative Research Group. Prevention of Atherosclerosis with Ramipril. , 2000, Journal of the American College of Cardiology.
[31] Bertram Pitt,et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial—the Losartan Heart Failure Survival Study ELITE II , 2000, The Lancet.
[32] Barry R. Davis,et al. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group. , 2000, JAMA.
[33] S. Yusuf,et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. , 2000 .
[34] T. Hedner,et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study , 1999, The Lancet.
[35] Mark Woodward,et al. Epidemiology: Study Design and Data Analysis , 1999 .
[36] L. Niskanen,et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial , 1999, The Lancet.
[37] Philip D. Harvey,et al. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39 , 1998, BMJ.
[38] Simon Davies,et al. Epidemiology: Study Design and Data Analysis (2nd ed.) , 2006 .
[39] Eric J Topol,et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. , 2004, JAMA.
[40] S. Yusuf,et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting enzyme inhibitors: the CHARM-alternative trial , 2004 .
[41] M. Woodward,et al. Effects of different blood pressure lowering regimens on major cardiovascular events: second cycle of prospectively designed overviews , 2003 .
[42] Teven,et al. EFFECTS OF LOSARTAN ON RENAL AND CARDIOVASCULAR OUTCOMES IN TYPE 2 DIABETES AND NEPHROPATHY EFFECTS OF LOSARTAN ON RENAL AND CARDIOVASCULAR OUTCOMES IN PATIENTS WITH TYPE 2 DIABETES AND NEPHROPATHY , 2001 .
[43] S. Yusuf,et al. Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000;342:145-53. , 2000 .
[44] Illiam,et al. THE EFFECT OF NISOLDIPINE AS COMPARED WITH ENALAPRIL ON CARDIOVASCULAR OUTCOMES IN PATIENTS WITH NON-INSULIN-DEPENDENT DIABETES AND HYPERTENSION , 2000 .
[45] S. MacMahon,et al. The world health organization—International society of hypertension blood pressure lowering treatment trialists’ collaboration: Prospective collaborative overviews of major randomized trials of blood pressure-lowering treatments , 1999, Current hypertension reports.
[46] R. Collins,et al. Protocol for prospective collaborative overviews of major randomized trials of blood-pressure-lowering treatments. World Health Organization-International Society of Hypertension Blood Pressure Lowering Treatment Trialists' Collaboration. , 1998, Journal of hypertension.